Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers

This study has been completed.
Information provided by:
Taipei Medical University WanFang Hospital Identifier:
First received: June 8, 2010
Last updated: NA
Last verified: June 2010
History: No changes posted

Evaluate chemotherapy related tumor markers on non small cell lung cancer by fluorescent in situ hybridization and immunohistochemistry, targets to be studied include EGFR, c-MET, topoisomerase II, p53, topoisomerase I, thymidylate synthase, ERCC1, tau, c-myc, RRM1, class III tubulin. These targets have been chosen because they are targets for chemotherapeutic agents that are currently used in clinical management of these diseases. In total 50 specimen will be studied, approximately one third have mutations/deletions of the EGFR gene.To attempt to establish a correlation between the pre-selected tumor markers and response to chemotherapy, and thus to be able to create a clinically useful classification that would provide clinical guidance for selection of the most effective chemotherapy for a individual patient, and thus be able to logically design more effective clinical trials for the future.

Lung Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers

Resource links provided by NLM:

Further study details as provided by Taipei Medical University WanFang Hospital:

Biospecimen Retention:   Samples With DNA


Enrollment: 90
Study Start Date: May 2009
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

lung cancer patient in wanfang hospital


Inclusion Criteria:

  • Patients with histologically confirmed lung cancer who received standard platinum-containing doublet chemotherapy followed by EGFR tyrosine kinase inhibitors.

Exclusion Criteria:

  • non
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01141686

Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Principal Investigator: Hsin-Gjin Eugene Liu Taipei Medical University WanFang Hospital
  More Information

No publications provided

Responsible Party: Hsingjin Eugene Liu, MD PhD, Taipei Medical University WanFang Hospital Identifier: NCT01141686     History of Changes
Other Study ID Numbers: IRB98021
Study First Received: June 8, 2010
Last Updated: June 8, 2010
Health Authority: Taiwan: Department of Health

Keywords provided by Taipei Medical University WanFang Hospital:
lung cancer

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Lung Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms processed this record on March 03, 2015